ID Name Structure References (top 5) Molecular Target(s)


in 1 ingredients:

  • 614
  • in 3 recipes:

  • 18
  • 236
  • 473

  • Properties
    C20H23N7O7    473.44

    1:  Baldwin J.
    FDA evaluating oxaliplatin for advanced colorectal cancer treatment.
    J Natl Cancer Inst.    impact factor:   12.945
    2002;  94(16): 1191-3

    2:  Punt CJ, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, Barone C, Fountzilas G, Riess H, Moylan E, Jones D, Dethling J, Colman J, Coward L, MacGregor S.
    Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study.
    Lancet.    impact factor:   10.197
    2002;  360(9334): 671-7

    3:  Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, Randlev B, Heise C, Uprichard M, Hatfield M, Rome L, Rubin J, Kirn D.
    Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.
    Cancer Res.    impact factor:   8.614
    2002;  62(21): 6070-9

    4:  Falcone A, Masi G, Allegrini G, Danesi R, Pfanner E, Brunetti IM, Di Paolo A, Cupini S, Del Tacca M, Conte P.
    Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
    J Clin Oncol.    impact factor:   7.963
    2002;  20(19): 4006-14

    5:  Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, Vincent MD, Lembersky BC, Thompson S, Maniero A, Benner SE.
    Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    J Clin Oncol.    impact factor:   7.963
    2002;  20(17): 3605-16

    Time used: 484 milliseconds.

    Webpage designed by Dr. Xueliang Fang, last updated on 3/10/2005